Next Century Growth Investors LLC Sells 2,853 Shares of Boston Scientific Corporation $BSX

Key Points

• Next Century Growth Investors LLC has reduced its stake in Boston Scientific by 14.0%, selling 2,853 shares in the first quarter, leaving them with 17,569 shares valued at approximately $1.77 million.
• Boston Scientific's CEO, Michael F. Mahoney, sold 164,443 shares worth over $17 million, resulting in a 10.02% decrease in his ownership stake.
• Equities analysts have shown optimism for Boston Scientific, with several firms upgrading the stock, leading to a consensus rating of "Buy" and an average price target of $117.50.

Next Century Growth Investors LLC trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 14.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,569 shares of the medical equipment provider's stock after selling 2,853 shares during the period. Next Century Growth Investors LLC's holdings in Boston Scientific were worth $1,772,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares during the last quarter. Investment Management Corp VA ADV purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter valued at about $27,000. Finally, Ameriflex Group Inc. purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $31,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research analyst reports. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Leerink Partners initiated coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price target on the stock. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Morgan Stanley upped their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $117.50.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 180,586 shares of company stock worth $18,925,509. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 1.2%

Shares of NYSE:BSX traded up $1.30 during trading on Tuesday, reaching $106.80. 4,513,508 shares of the stock traded hands, compared to its average volume of 7,464,242. The stock has a 50-day moving average of $104.60 and a two-hundred day moving average of $102.11. Boston Scientific Corporation has a 52-week low of $80.50 and a 52-week high of $108.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $158.25 billion, a P/E ratio of 63.57, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The business's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.